ArticleFrontiers in genetics2020
Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas.
Article in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Pathomics-based machine learning models for predicting METTL5 expression and prognosis in lung adenocarcinoma.Journal of thoracic disease · 2026Article
- N6 methyl adenosine-stabilized microtubule actin crosslinking factor 1 ameliorates staphylococcal protein A-induced damage in osteocyte-like MLO-Y4 cells.Journal of bioenergetics and biomembranes · 2026Article
- Significance of Methyltransferase-like 5 Expression in Oral Squamous Cell Carcinoma.International dental journal · 2026Article
- Dynamic ecosystems of tumor drug resistance mechanisms: from molecular heterogeneity to systemic interventions.Apoptosis : an international journal on programmed cell death · 2026Review
- METTL5-mediated m6A modification of 18S rRNA drives oral squamous cell carcinoma progression by enhancing CCND3 translation.Oncology letters · 2026Article
- mFrontiers in cell and developmental biology · 2026Review
- Prognostic role and mutational characteristics of N6-methyladenosine-related genes in lung adenocarcinoma.Oncology letters · 2025Article
- METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.Future oncology (London, England) · 2025Article
- Targeting methyltransferase-like 5-mediated sphingomyelin metabolism: A novel therapeutic approach in gastric cancer.World journal of gastrointestinal oncology · 2024Article
- Expression of Pivotal Long Non-coding RNAs Implicated in Gastric Cancer: A Bioinformatic and Clinical Study.Biochemical genetics · 2024Article
- Gene polymorphisms ofJournal of Cancer · 2024Article
- Ghost authors revealed: The structure and function of human NWiley interdisciplinary reviews. RNA · 2023Review
- METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment.Scientific reports · 2023Article
- N6-methyladenosine (m6A) modification of ribosomal RNAs (rRNAs): Critical roles in mRNA translation and diseases.Genes & diseases · 2023Review
- Article
- Role of m6A writers, erasers and readers in cancer.Experimental hematology & oncology · 2022Review
- The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma.Bioengineered · 2022Article
- mBMC medicine · 2021Article
- Expression and prognostic potential of ribosome 18S RNA mCancer cell international · 2021Article
- N6-methyladenosine methyltransferases: functions, regulation, and clinical potential.Journal of hematology & oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For lung adenocarcinoma (LUAD), patients of different stages have strong heterogeneity, and their overall prognosis varies greatly. Thus, exploration of novel biomarkers to better clarify the characteristics of LUAD is urgent. Multi-omics information of LUAD patients were collected form TCGA. Three independent LUAD cohorts were obtained from gene expression omnibus (GEO). A multi-omics correlation analysis of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.